Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22383Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Nicolaides, C. | en |
| dc.contributor.author | Bafaloukos, D. | en |
| dc.contributor.author | Kalogera-Fountzila, A. | en |
| dc.contributor.author | Kalofonos, H. | en |
| dc.contributor.author | Samelis, G. | en |
| dc.contributor.author | Aravantinos, G. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:23:54Z | - |
| dc.date.available | 2015-11-24T19:23:54Z | - |
| dc.identifier.issn | 0735-7907 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22383 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Antibiotics, Antineoplastic/*therapeutic use | en |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | en |
| dc.subject | Breast Neoplasms/*drug therapy/mortality | en |
| dc.subject | Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives | en |
| dc.subject | Drug Resistance, Neoplasm | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Middle Aged | en |
| dc.subject | Paclitaxel/administration & dosage/adverse effects/*analogs & derivatives | en |
| dc.subject | Patient Compliance | en |
| dc.subject | Survival Rate | en |
| dc.subject | *Taxoids | en |
| dc.title | Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10923097 | - |
| heal.identifier.secondary | http://informahealthcare.com/doi/abs/10.3109/07357900009012188 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2000 | - |
| heal.abstract | A phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a median performance status of 1 (range, 0-2) were enrolled in the study. Treatment consisted of docetaxel 75 mg/m2 in a 1-hr infusion on day 1 preceded by gemcitabine 1000 mg/m2 over 30 min on days 1 and 8. One hundred eighty-one treatment cycles were administered, 113 (62.4%) of them at full dose. Relative dose intensity of gemcitabine and of docetaxel was 0.73 and 0.85, respectively. More common grade 3-4 toxicities included neutropenia (49%), anemia (10%), fatigue (10%), nausea/vomiting (8%), and alopecia (77%). Seven patients were hospitalized for febrile neutropenia. Granulocyte colony-stimulating factor (G-CSF) administration was required in 90% of patients. Overall, 14 patients (36%) responded, 3 (7.5%) of them completely. Median duration of response was 10.3 months (range, 4.6-17.5+). Median time to progression was 7 months (range, 0.2-17.5+) and median survival 12.7 months (range, 2-20.5+). In conclusion, the combination of docetaxel and gemcitabine, as used in the present study, has moderate activity in anthracycline-resistant ABC. Future studies should incorporate prophylactic administration of G-CSF to reduce the incidence of febrile neutropenia and maintain dose intensity. | en |
| heal.journalName | Cancer Invest | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
